Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 24, 2020, Michael A. Kelly was appointed to serve on the Board of Directors (the "Board") of DMC Global Inc. (the "Company").

Mr. Kelly has more than two decades of executive experience in senior leadership roles in the life sciences industry. He founded and has served as President of Sentry Hill Partners, LLC, a global life sciences transformation and management consulting business, since January 2018. Mr. Kelly worked in various capacities at Amgen, Inc. from 2003 to 2017, most recently as Senior Vice President, Global Business Services from July 2014 to July 2017, and as acting Chief Financial Officer from January to July 2014. Prior to his service at Amgen, he served as Chief Financial Officer of Tanox, Inc. (2000 to 2003), Vice President, Finance and Corporate Controller of Biogen, Inc. (1998 to 2000) and Vice President, Finance and Chief Financial Officer of Nutrasweet Kelco Company (1996 to 1998). He currently serves on the board of directors of HOOKIPA Pharma, Inc., a public biopharmaceutical company, where he serves as an independent director and audit committee chair. Mr. Kelly holds a bachelor's degree in Business Administration from Florida A&M University.

The Board did not appoint Mr. Kelly to serve on any committees at this time.

There are no family relationships between Mr. Kelly and any officer or other director of the Company or any related party transactions involving Mr. Kelly and the Company. There is no arrangement or understanding between Mr. Kelly and any other person pursuant to which he was selected as a director.

On July 24, 2020, Mr. Kelly received a grant of restricted stock awards with an aggregate grant date fair value of $60,000, computed in accordance with FASB ASC Topic 718. Mr. Kelly will be compensated for his service as a director in accordance with the Company's standard director compensation program.

A copy of the press release announcing Mr. Kelly's appointment is included as Exhibit 99.1 hereto.

Item 9.01 Financial Statements and Exhibits.



(d)                 Exhibits.

Exhibit Number               Description
                  99.1         Press Release, dated July 2    7    , 2020.

                             Cover Page Interactive Data File (embedded within the Inline XBRL
                   104       document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses